Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI108942

Control of 3-Hydroxy-3-Methylglutaryl-CoA Reductase Activity in Cultured Human Fibroblasts by Very Low Density Lipoproteins of Subjects with Hypertriglyceridemia

Sandra H. Gianturco, Antonio M. Gotto Jr., Richard L. Jackson, Josef R. Patsch, Harley D. Sybers, O. David Taunton, Daniel L. Yeshurun, and Louis C. Smith

Department of Medicine, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Department of Biochemistry, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Department of Pathology, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Find articles by Gianturco, S. in: PubMed | Google Scholar

Department of Medicine, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Department of Biochemistry, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Department of Pathology, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Find articles by Gotto, A. in: PubMed | Google Scholar

Department of Medicine, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Department of Biochemistry, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Department of Pathology, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Find articles by Jackson, R. in: PubMed | Google Scholar

Department of Medicine, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Department of Biochemistry, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Department of Pathology, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Find articles by Patsch, J. in: PubMed | Google Scholar

Department of Medicine, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Department of Biochemistry, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Department of Pathology, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Find articles by Sybers, H. in: PubMed | Google Scholar

Department of Medicine, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Department of Biochemistry, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Department of Pathology, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Find articles by Taunton, O. in: PubMed | Google Scholar

Department of Medicine, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Department of Biochemistry, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Department of Pathology, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Find articles by Yeshurun, D. in: PubMed | Google Scholar

Department of Medicine, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Department of Biochemistry, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Department of Pathology, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030

Find articles by Smith, L. in: PubMed | Google Scholar

Published February 1, 1978 - More info

Published in Volume 61, Issue 2 on February 1, 1978
J Clin Invest. 1978;61(2):320–328. https://doi.org/10.1172/JCI108942.
© 1978 The American Society for Clinical Investigation
Published February 1, 1978 - Version history
View PDF
Abstract

Very low density lipoproteins (VLDL) and low density lipoproteins (LDL) from human normolipemic plasma, and the VLDL, the intermediate density lipoprotein (IDL), and LDL from patients with Type III hyperlipoproteinemic plasma were tested for their abilities to suppress the activity of 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG-CoA) reductase in cultured human fibroblasts from normal subjects and a Type III patient. Regulation of cholesterol synthesis in the fibroblasts of a patient with Type III hyperlipoproteinemia appears to be normal. VLDL from normal subjects, isolated by angle head ultracentrifugation (d < 1.006) or by gel filtration on BioGel A-5m, were about 5 times less effective than LDL in suppressing HMG-CoA reductase activity, based on protein content, in agreement with previous reports with normal fibroblasts. Zonal centrifugation of normal VLDL isolated by both methods showed that the VLDL contained IDL. Normal VLDL from the angle head rotor, refractionated by the zonal method, had little, if any, ability to suppress the HMG-CoA reductase activity in either normal or Type III fibroblasts. VLDL, IDL, and LDL fractionated by zonal ultracentrifugation from Type III plasma gave half-maximum inhibition at 0.2-0.5 μg of protein/ml, indistinguishable from the suppression caused by normal LDL. Type III VLDL did not suppress HMG-CoA reductase in mutant LDL receptor-negative fibroblasts. Zonally isolated VLDL obtained from one Type IV and one Type V patient gave half-maximal suppression at 5 and 0.5 μg of protein/ml, respectively. Molecular diameters and apoprotein compositions of the zonally isolated normal and Type III VLDL were similar; the major difference in composition was that Type III VLDL contained more cholesteryl esters and less triglyceride than did normal VLDL. The compositions and diameters of the Type IV and Type V VLDL were similar to normal VLDL. These findings show that the basic defect in Type III hyperlipoproteinemia is qualitatively different from the cellular defect found in familial hypercholesterolemia, since the regulation of HMG-CoA reductase activity is normal in Type III fibroblasts. The metabolic defect in hypertriglyceridemia is related to the triglyceriderich lipoproteins which, free of other lipoproteins, have an enhanced ability to interact with cultured fibroblasts to regulate HMG-CoA reductase activity. These studies suggest that, in hypertriglyceridemia, there is a mechanism for direct cellular catabolism of VLDL which is not functional for normal VLDL.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 320
page 320
icon of scanned page 321
page 321
icon of scanned page 322
page 322
icon of scanned page 323
page 323
icon of scanned page 324
page 324
icon of scanned page 325
page 325
icon of scanned page 326
page 326
icon of scanned page 327
page 327
icon of scanned page 328
page 328
Version history
  • Version 1 (February 1, 1978): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts